(Q34501008)

2 August 2017

Effects of Depression and Serotonergic Antidepressants on Bone: Mechanisms and Implications for the Treatment of Depression (English)

1 reference

2 August 2017

Brisa S Fernandes

1

0 references

Lana J. Williams

object named as

Lana J Williams

series ordinal

5

0 references

Michael Berk

object named as

Michael Berk

series ordinal

4

0 references

Julie A. Pasco

series ordinal

3

object named as

Julie A Pasco

1 reference

2 August 2017

Jason M Hodge

2

1 reference

2 August 2017

7 November 2015

1 reference

2 August 2017

1 reference

2 August 2017

33

1 reference

2 August 2017

1

1 reference

2 August 2017

21-25

1 reference

https://scigraph.springernature.com/pub.10.1007/s40266-015-0323-4

2 August 2017

0 references

cites work

Epidemiology and outcomes of osteoporotic fractures

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

The human cost of fracture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

Depression following fracture in women: a study of age-matched cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

Depression and osteoporosis: epidemiology and potential mediating pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

Depression and bone metabolism. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

Major depression is a risk factor for low bone mineral density: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

Depression, selective serotonin reuptake inhibitors, and osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

Depression, antidepressants, and bone health in older adults: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

Trends in Prescribing of Selective Serotonin Reuptake Inhibitors and Other Newer Antidepressant Agents in Adult Primary Care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

Update in serotonin and bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

Selective serotonin reuptake inhibitors inhibit human osteoclast and osteoblast formation and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

The association of bone mineral density and depression in an older population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

The association between depressive and anxiety symptoms and bone mineral density in the general population: the HUNT Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

Low bone mass in premenopausal women with depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

Depression and low bone mineral density: a meta-analysis of epidemiologic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

Quantitative Heel Ultrasound (QUS) measures of bone quality in association with mood and anxiety disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

Effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening, prevention and management?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

Do SSRIs play a role in decreasing bone mineral density?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

The adverse skeletal effects of selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case-control studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

Tricyclic antidepressant use and risk of fractures: a meta-analysis of cohort and case-control studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

Antidepressant medications and osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

Use of selective serotonin reuptake inhibitors and risk of fracture: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

Effect of selective serotonin reuptake inhibitors on the risk of fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

Psychiatric disorders, psychotropic medication use and falls among women: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

Cellular and molecular mechanisms of bone remodeling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

The two faces of serotonin in bone biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

Decreased osteoclastogenesis in serotonin-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

Serotonin: good or bad for bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

Lrp5 functions in bone to regulate bone mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

Expression of serotonin receptors in bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

The serotonin 5-HT2B receptor controls bone mass via osteoblast recruitment and proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

Neural regulation of bone and the skeletal effects of serotonin (5-hydroxytryptamine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

Psychotropic drugs have contrasting skeletal effects that are independent of their effects on physical activity levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

Adult Tph2 knockout mice without brain serotonin have moderately elevated spine trabecular bone but moderately low cortical bone thickness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-015-0323-4

The "depressive" face of osteoporosis and the "osteoporotic" face of depression.

21 January 2018

1 reference

12 December 2020

Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: evidence from in vitro and animal-based studies

1 reference

12 December 2020

Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture

1 reference

12 December 2020

Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: evidence from clinical studies.

1 reference

12 December 2020

Consensus development conference: prophylaxis and treatment of osteoporosis

1 reference

12 December 2020

10.1007/S40266-015-0323-4

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

26547857